Nanostructured Lipid Carriers Can Enhance Oral Absorption of Khellin, a Natural Pleiotropic Molecule.
Caco-2 cells
cell viability
gastrointestinal stability
khellin
lyophilization
nanostructured lipid carriers
oral administration
permeability
release study
shelf life
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
17 Dec 2021
17 Dec 2021
Historique:
received:
14
11
2021
revised:
10
12
2021
accepted:
14
12
2021
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
12
2
2022
Statut:
epublish
Résumé
A novel formulation based on nanostructured lipid carriers (NLCs) was developed to increase solubility and intestinal absorption of khellin. K-NLCs were prepared with stearic acid, hempseed oil, Brij S20, and Labrafil M 1944 CS, using the emulsification-ultrasonication method. Developed nanoparticles were chemically and physically characterized by liquid chromatography, light scattering techniques, and electron microscopy. The size, about 200 nm, was optimal for oral delivery, and the polydispersity index (around 0.26), indicated high sample homogeneity. Additionally, K-NLCs showed a spherical morphology without aggregation by microscopic analysis. The encapsulation efficiency of khellin was about 55%. In vitro release studies were carried out in media with different pH to mimic physiological conditions. K-NLCs were found to be physically stable in the simulated gastric and intestinal fluids, and they preserved about 70% of khellin after 6 h incubation. K-NLCs were also successfully lyophilized testing different lyoprotectants, and obtained freeze-dried K-NLCs demonstrated good shelf life over a month. Lastly, permeability studies on Caco-2 cells were performed to predict khellin passive diffusion across the intestinal epithelium, demonstrating that nanoparticles increased khellin permeability by more than two orders of magnitude. Accordingly, developed NLCs loaded with khellin represent a versatile formulation with good biopharmaceutical properties for oral administration, possibly enhancing khellin's bioavailability and therapeutic effects.
Identifiants
pubmed: 34946734
pii: molecules26247657
doi: 10.3390/molecules26247657
pmc: PMC8705784
pii:
doi:
Substances chimiques
Plant Extracts
0
Stearic Acids
0
stearic acid
4ELV7Z65AP
Khellin
5G117T0TJZ
hempseed oil
69VJ1LPN1S
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : University of Florence
ID : RICATEN 2020
Références
Int J Biol Macromol. 2019 May 15;129:267-280
pubmed: 30726749
Planta Med. 2017 Mar;83(5):366-381
pubmed: 28178749
Pharmaceutics. 2021 Feb 26;13(3):
pubmed: 33652886
Molecules. 2021 Apr 07;26(8):
pubmed: 33917147
Eur J Pharm Biopharm. 2016 Dec;109:113-121
pubmed: 27693677
Eur J Dermatol. 2001 May-Jun;11(3):225-9
pubmed: 11358729
J Control Release. 2016 Sep 28;238:176-185
pubmed: 27480450
Mol Pharm. 2014 Sep 2;11(9):3039-47
pubmed: 25115349
Int J Biol Macromol. 2020 Dec 1;164:232-241
pubmed: 32682035
Int J Pharm. 2016 Sep 10;511(1):524-537
pubmed: 27452421
Int J Pharm. 2021 Sep 25;607:121036
pubmed: 34438005
Adv Drug Deliv Rev. 2007 Jul 30;59(7):667-76
pubmed: 17618704
Int J Nanomedicine. 2018 Jun 28;13:3781-3793
pubmed: 29988733
Pharmacol Ther. 1989;44(3):407-43
pubmed: 2519349
Eur J Pharm Biopharm. 2016 May;102:87-91
pubmed: 26952905
Molecules. 2020 Jul 08;25(14):
pubmed: 32650414
Future Sci OA. 2016 Jul 15;2(3):FSO135
pubmed: 28031979
Eur J Pharm Biopharm. 2003 Mar;55(2):181-4
pubmed: 12637094
Adv Drug Deliv Rev. 2018 Jan 15;124:125-139
pubmed: 28882703
Curr Med Chem. 2019;26(24):4631-4656
pubmed: 30381065
Drug Dev Ind Pharm. 2017 Nov;43(11):1743-1758
pubmed: 28673096
Molecules. 2020 Jan 12;25(2):
pubmed: 31940874
Int J Nanomedicine. 2016 Dec 30;12:305-315
pubmed: 28115848
Int J Pharm. 2009 Oct 1;380(1-2):133-41
pubmed: 19635537
J Pharm Sci. 2000 Apr;89(4):429-42
pubmed: 10737905
Food Chem. 2021 May 15;344:128670
pubmed: 33272755
Pharmaceutics. 2021 Aug 17;13(8):
pubmed: 34452236
Recent Pat Nanotechnol. 2021;15(2):154-164
pubmed: 32912129
Int J Biol Macromol. 2021 May 15;179:217-229
pubmed: 33662425
J Nucl Med Technol. 2016 Mar;44(1):12-8
pubmed: 26940448
Eur J Pharm Sci. 2006 Nov;29(3-4):278-87
pubmed: 16815001
J Pharm Sci. 2000 Aug;89(8):1073-84
pubmed: 10906731
Pharmaceutics. 2019 Dec 15;11(12):
pubmed: 31847489
Nat Protoc. 2007;2(9):2111-9
pubmed: 17853866